Zum Hauptinhalt springen
xMedica

NCT07326709ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…

Phase 3770 Teilnehmende gesucht117 Studienzentren27 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 41 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.

How this score is built
  • Enrolment28/40

    770 participants (target)

  • Site count19/25

    41 sites

  • Country count12/15

    9 countries

  • Planned duration9/10

    Planned over about 50 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,104 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.

This study will have a variable double-blind treatment duration of up to 36 months. As part of the study design, not every participant will complete 36 months of treatment. The study consists of 3 periods: * Screening Period: A period of up to 42-days to assess participants eligibility * Double-blind Treatment Period: This period will have variable individual treatment duration, up to 36 months. The double-blind treatment period concludes when ≥50% patients complete Month 36. The maximum treatment duration for an individual participant is 36 months. * Safety Follow-up Period: A period consisting of one safety follow-up visit, conducted on site or by phone call, for all participants not continuing treatment in the separate open-label extension study or discontinuing early. The visit/phone call will take place 30 days after End of Study (EOS)

Erkrankungen

  • Huntington Disease

Eignung

Eignung
GeschlechtAlle
Alter21 Years – 70 Years
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Signed informed consents must be obtained prior to participation in the study * Ambulatory male or female participants between 21 to 70 years of age, inclusive, on the day of Informed Consent signature * Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening. * Meets all of the following criteria: * UHDRS IS score ≥90 * UHDRS TFC score = 13 * UHDRS TMS score = 7-25, inclusive * CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) / 6.49 Exclusion Criteria: * History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD * Serologic evidence for active viral hepatitis as indicated by: * positive anti-HBc IgM * positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA * positive HCV ab test confirmed by positive HCV RNA * Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result * History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker * History of familial long QT syndrome or known family history of Torsade de Pointes * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. o WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 8 months after stopping study treatment. * Pregnant or nursing (breastfeeding) women Other protocol defined inclusion/exclusion criteria may apply

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme770 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Novartis Pharmaceuticals Sponsor

Studienarme und Interventionen

  • VotoplamEXPERIMENTAL

    Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

  • PlaceboPLACEBO_COMPARATOR

    Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

Interventionen

  • Arzneimittel Placebo

    Placebo

  • Arzneimittel Votoplam (blinded)

    Votoplam (blinded) active treatment

Endpunkte

  1. Primärer Endpunkt

    Change from Baseline in cUHDRS score

    The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.

    Zeitrahmen Baseline, Month 36

  2. Sekundärer Endpunkt

    Change from Baseline in UHDRS-TFC

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.

    Zeitrahmen Baseline, Month 36

  3. Sekundärer Endpunkt

    Change from Baseline in UHDRS-IS

    The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Zeitrahmen Baseline, Month 36

  4. Sekundärer Endpunkt

    The time to decline in TFC score by at least one or IS score by at least 10

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Zeitrahmen Baseline to end of treatment up to 36 months

  5. Sekundärer Endpunkt

    Change from Baseline in UHDRS-TMS

    The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.

    Zeitrahmen Baseline, Month 36

  6. Sekundärer Endpunkt

    Change from Baseline in SDMT

    The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.

    Zeitrahmen Baseline, Month 36

  7. Sekundärer Endpunkt

    Change from Baseline in SWRT

    The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.

    Zeitrahmen Baseline, Month 36

  8. Sekundärer Endpunkt

    Percent change from Baseline in blood mHTT protein

    The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.

    Zeitrahmen Baseline to steady state and up to 36 months in blood mHTT protein

  9. Sekundärer Endpunkt

    Change from Baseline in serum NfL

    Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.

    Zeitrahmen Baseline, Month 36

  10. Sekundärer Endpunkt

    Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal

    Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.

    Zeitrahmen Baseline to up to 36 months

Daten

Daten
Startdatum24. März 2026 (tatsächlich)
Primärer Abschluss2. April 2030 (geschätzt)
Abschluss30. April 2030 (geschätzt)
Erstveröffentlichung8. Januar 2026 (tatsächlich)
Zuletzt aktualisiert22. September 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtSeptember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

117 Studienzentren rekrutieren

Argentina

Argentina
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBuenos AiresRekrutiert
Instituto Argentino de Investigación Neurológica (IADIN)CABABuenos AiresRekrutiert
Centro de Investigaciones Metabólicas (CINME)CABABuenos AiresRekrutiert
Novartis Investigative SiteCiudad deBuenos AiresRekrutiert

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteCaulfield SouthVictoriaRekrutiert
Novartis Investigative SiteWestmeadNew South WalesRekrutiert

Belgium

Belgium
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteLeuvenVlaams BrabantRekrutiert

Bulgaria

Bulgaria
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteSofiaRekrutiert
Novartis Investigative SiteSofiaRekrutiert

Canada

Canada
EinrichtungStadtBundesland oder RegionStatus
CUSM Montreal Neurological InstituteMontrealQuebecRekrutiert
Centre de recherche du CHUMMontrealQuebecRekrutiert
North York General HospitalNorth YorkOntarioRekrutiert

China

China
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBeijingRekrutiert
Novartis Investigative SiteBeijingRekrutiert
The Second Xiangya Hospital of Central South UniversityChangshaHunanRekrutiert
West China Hospital of Sichuan UniChengduSichuanRekrutiert
Novartis Investigative SiteFuzhouFujianRekrutiert
Novartis Investigative SiteGuangzhouGuangdongRekrutiert
Novartis Investigative SiteGuangzhouGuangdongRekrutiert
The Second Affiliated Hosp Of Zhejiang Univ School Of MedicineHangzhouZhejiangRekrutiert
Novartis Investigative SiteShanghaiRekrutiert
Tongji Hos Affiliated Tongji Medical College of HuazhongWuhanHubeiRekrutiert

Colombia

Colombia
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteMedellínRekrutiert

Czechia

Czechia
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBrnoRekrutiert
Novartis Investigative SitePragueRekrutiert

Denmark

Denmark
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteCopenhagenRekrutiert

France

France
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteAngersFranceRekrutiert
Novartis Investigative SiteMarseilleRekrutiert
Novartis Investigative SiteMontpellierRekrutiert

Germany

Germany
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteAachenRekrutiert
Novartis Investigative SiteBochumRekrutiert
Novartis Investigative SiteMünsterRekrutiert
Novartis Investigative SiteTübingenRekrutiert
Novartis Investigative SiteUlmRekrutiert

Hungary

Hungary
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBudapestRekrutiert
Novartis Investigative SiteSzegedRekrutiert

Israel

Israel
EinrichtungStadtBundesland oder RegionStatus
Tel Aviv Sourasky Med Ctr IchilovTel AvivRekrutiert

Italy

Italy
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBolognaBORekrutiert
Novartis Investigative SiteBresciaBSRekrutiert
Novartis Investigative SiteMilanMIRekrutiert
Novartis Investigative SiteMilanMIRekrutiert

Japan

Japan
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBunkyo KuTokyoRekrutiert
Novartis Investigative SiteKashiharaNaraRekrutiert
Novartis Investigative SiteSagamiharaKanagawaRekrutiert

Netherlands

Netherlands
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteLeidenSouth HollandRekrutiert
Novartis Investigative SiteMaastrichtLimburgRekrutiert

Poland

Poland
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteKrakowPOLRekrutiert

Portugal

Portugal
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteLisbonRekrutiert
Novartis Investigative SitePortoRekrutiert

Romania

Romania
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBucharestRekrutiert

67 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 22. September 2026

    Studienzentrum hinzugefügt

    35 sites added (117 total)

    82117

  2. 31. August 2026

    Studienzentrum hinzugefügt

    22 sites added (82 total)

    6082

  3. 11. August 2026

    Studienzentrum hinzugefügt

    9 sites added (60 total)

    5160

  4. 29. Juli 2026

    Studienzentrum hinzugefügt

    10 sites added (51 total)

    4151